Medical Devices

Parnell’s nixiFLOR, the first generic of Resflor Gold®, offers a cost-effective new weapon for ranchers battling Bovine Respiratory Disease.

A startling new study reveals a sharp rise in diagnosed anxiety, highlighting a growing public health crisis and an urgent need for treatment innovation.

Merz Aesthetics secures key EU approvals for its BELOTERO® Balance filler, offering a precise, evidence-backed solution for tired eyes and forehead lines.

Despite a revenue dip, Kelyniam Global slashed its net loss, secured FDA clearance for a breakthrough implant, and rejected a buyout, charting its own course.

Data shows Beren Therapeutics' drug slows progression and boosts survival for infantile-onset NPC, a rare disorder with no approved US treatments.

The world's top implant seller by volume is building an empire on precision manufacturing, massive R&D, and a strategy to control the entire dental workflow.

Japan becomes the first nation outside Israel to approve Alpha DaRT, a highly precise therapy for untreatable head and neck cancers. Here’s what it means.

K-beauty brand Centellian24 partners with TOMORROW X TOGETHER's TAEHYUN, a strategic move to capture the booming US market and a new generation of fans.

Fresh off strong 2025 earnings, AtriCure will detail its growth strategy and innovative cardiac portfolio at a major life sciences conference.

With a promise of cellular renewal via exosomes, (plated) Skin Science is leading a biotech revolution. But can it navigate the hype and regulatory hurdles?

Amidst industry-wide regulatory challenges, Meridian secures critical IVDR certification for its Alethia assays, ensuring continued market access in Europe.

A pivotal trial for a rare muscle disease failed its main goal, but promising data in a specific patient group offers a new, complex path forward.

The AI health platform's latest acquisition integrates a specialized pregnancy app, promising a new era of proactive, data-driven maternal care for families.

Acquiring Complete Genomics, Swiss Rockets unveils its CoolMPS 600, a bid to democratize long-read sequencing with breakthrough cost and accuracy.

Machina Medical's novel hydrogel barrier, MFUSE, gains FDA clearance, promising to control severe bleeding in seconds and disrupt the hemostasis market.

A new tri-specific antibody, IM1240, safely hits cancer cells at massive doses in preclinical studies, potentially solving a key toxicity problem in immunotherapy.

With FDA alignment for its pivotal Phase 3 trial, Oncolytics Biotech is poised to bring the first immunotherapy to the challenging pancreatic cancer landscape.